SAN FRANCISCO — A woman in Nevada cash in one’s chips in September from an transmission that resisted every sort of antibiotic we have in the US that could have cure it .

The case , which the Centers for Disease Control and Preventionreported Thursday , is part of the growing trouble of antibiotic resistance , which is await to kill10 million hoi polloi annually by 2050 .

" I think it ’s concerning , " Alexander Kallen , a medical officer at the CDC ’s class of healthcare quality promotion , tell Stat News . " We have relied for so long on just Modern and newer antibiotics . But obviously the bugs can often [ develop resistance ] faster than we can make new one . "

That ’s in part because it bring a long meter to make grow antibiotics , and even those that have made it through development face stumbling blocks . As a result , many major pharmaceutical companies have stopped developing new antibiotic totally .

Last yr , for lesson , the Food and Drug Administration turned downCempra pharmaceutic ' novel antibiotic drug , a drug called solithromycin , which was plan to fight a eccentric of bacterial pneumonia . The FDA cited , in part , too little information on howthe drug might pretend the liver . It commend an additional trial run that would require testing the antibiotic on 9,000 people , according to Cempra .

Why it ’s so hard to get new antibiotics sanction

Despite these roadblocks , the biotech caller Paratek Pharmaceuticals is currently working on a new antibiotic drug called omadacycline . So far , the approval process for the drug has take roughly two decades .

The drug would treat skin infections , pneumonia , and urinary tract infection . The ship’s company expects solvent by July from phase - three trial looking at skin infections and pneumonia .

" After 21 age of investment … we will have the polar data point , " Paratek President Evan Loh told Business Insider at the JPMorgan Healthcare Conference on Thursday . If the drug gets on the grocery store , it will have been 15 class since it went into human trials , he said .

So why does it take so long ? Part of the problem is just guileful skill — screen out through different compounds to visualize out which antibiotic might make can take fourth dimension . But it also has a lot to do with the companies running the trials staying afloat financially , Loh said .

And at that point , sometimes legislation can come in W. C. Handy . Loh said theGAIN Acthelped Paratek " save the company " by extending its patent on its antibiotic by five years . The act , which passed in 2012 , draw a bead on to incentivize companies to rise antibiotic drug by giving them surplus clock time under patent aegis to make money before confront generic competition .

If sanction , Paratek ’s new drug will be impart to the arsenal of medicines design to take on repellent bacterium , which will be key as more deaths are ascribe to antibiotic - resistive bacterium .

" In the pre - antibiotic era , people were utter by the metre they were 30 because of contagion , " Adam Woodrow , Paratek ’s chief commercial officer , differentiate Business Insider . " Can you ever imagine that scenario where we get back to that situation ?

" There was once this clock time where we were keeping up . Now we ’ve sort of fallen behind , " say Woodrow . " And the group of antibiotic drug that should be there to battle these pathogen have just disappeared . "

learn the original article onTech Insider . Copyright 2016 .

NOW WATCH : A Harvard business prof explains a legal grade of ' insider trading ' in America